PC945 is the only anti-fungal that has been specifically developed as an inhaled treatment for pulmonary aspergillosis. It has been designed to deliver high local lung concentrations, and to ensure a long duration of action and minimal systemic exposure.

PC945 is 30- to 100-fold more potent than voriconazole against Aspergillus fumigatus and exhibits minimal systemic bioavailability after inhaled administration and is intended for delivery by a standard, off-the-shelf nebulizer (Colley 2017).

PC945 has been used on a “special needs” basis in the UK in patients who have not responded to multiple standard-of-care (SOC) antifungal therapies, with remarkable results. As of January 2021, of the eleven (11) patients treated, positive clinical results were observed in nine (9) patients.

A Phase 3 study of PC945 for adults, who have limited or no alternative treatment options, for the treatment of invasive pulmonary aspergillus disease as part of a combined antifungal regimen will be initiated in 2022.




  • “Based on results to date in patients who have already failed multiple treatment options, we believe PC945 has the potential to significantly improve response rates while minimizing any additional toxicity burden and drug-drug interactions that are frequently seen with systemic approaches."”

    Dan Burgess
  • “It is gratifying to see PC945 producing the responses we designed it to achieve in patients who have failed existing therapies. We’re looking forward to exploring these findings more fully in studies in both acutely and chronically ill patients.”

    Pete Strong